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Summary 
Five patients with idiopathic Parkinson’s disease with severe response fluctuations were selected for a randomized 
double-blind placebo-controlled study, concerning the clinical effects of subcutaneous apomorphine and its assessment 
in ‘off -periods. The study was designed as five n = 1 studies, in which every patient was his own control. The effect of 
apomorphine was studied by using the Columbia rating scale and quantitative assessments, using tapping, walking and 
pinboard. There was a significant positive effect of apomorphine, in a mean optimal dose of 2.7 mg, with a mean latency 
of onset of 7.3 min and a mean duration of response of 96 min. After pretreatment with domperidone, no significant 
adverse effects were observed. Tapping showed the highest correlation with rigidity and bradykinesia. Walking showed 
a high correlation with stability and gait. Pinboard testing did not give additional information. The first conclusion was 
that apomorphine proved to be a significantly effective dopamine agonist, proven now also by a double blind placebo- 
controled study. Secondly it was concluded that assessment of clinicai effect in parkinsonian patients can be performed 
best by combining the Columbia item tremor with tapping and walking scores. 
Introduction 
The incidence of disabling “on-off fluctuations in 
Parkinson’s disease (PD) increases with the duration of 
levodopa treatment. After 10 years of sustained therapy, 
most patients are affected [I]. Once established, severe 
motor ~uctuations are difficult to manage with changes 
in prescription strategies, e.g. dose-fractioning, sus- 
tained-release medication and dopamine agonists. Since 
1987, apomorphine, a potent directly acting dopamine 
agonist, has been introduced as a subcutaneous injection 
C~~ri?~~po~~e~(.~ to: T. van Laar, MD, Depa~ment of Neurology. 
Leiden University Hospital, Rijnsburgerweg 10, P.O. Box 9600, 2300 
RC Leiden. The Netherlands. Tel.: OX-2621 11. 
therapy in PD [2]. Many authors have published the po- 
sive effects of subcutaneous apomorphine. in reversing 
the ‘off -period motor deficits 13-61. None of these stud- 
ies, however, used a placebo-controlled esign and most 
studies had a short fohow-up, in which placebo effects 
could not be excluded. Placebo effects can not be ig- 
nored, as was shown in the study with the dopamine ag- 
onist pergohde, by Olanow et al. [7]. 
There is only one previous report of a placebo-con- 
trolled study with apomorphine [8]. In this study with 8 
patients, all patients only received 1 mg apomorphine, 
without domperidone pretreatment and whilst taking 
their usual mediation. Therefore. we did a randomized 
double-blind placebo-controlled study in 5 patients, to 
evaluate the statistical significance of the clinical benefit 
of subcutaneous administered apomorphine. We also 
considered the correlation between clinical and yuantita- 
tive assessments of these patients. Pharmacokinetic para- 
meters and their relation to the clinical efficacy of apo- 
morphine have also been studied. 
Patients and m&hods 
Five patients, two women and three men, with idio- 
pathic PD, mean age of 54.2 years (range 29-68 years) 
and a mean duration of PD of 12.4 years (range 7-23 
years), were selected for this study. One patient already 
showed parkinsonian symptoms at the age of 22. How- 
ever, extensive laboratory analysis and CT-scanning of 
the brain did not reveal any abnormality. Therefore this 
patient also was included in this study. Three patients 
were in Hoehn and Yahr stage IV and two patients in 
stage III. They had used levodopa medication with a pe- 
ripheral decarboxylase inhibitor for 9.6 years (range 2- 
20 years). All patients had had response fluctuations for 
at least half a year. Their anti-parkinsonian medication 
was kept unchanged for at least 1 month prior to the 
study. All conventional methods to improve their re- 
sponse fluctuations had failed. 
Patients with other neurological or general internal 
diseases were excluded, as well as patients with a mini 
mental state examination (MMSE) of less than 24 points. 
All patients gave informed consent and the study was 
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approved by the Medical Ethical Committee of the hos- 
pital. The patients were admitted for one week during the 
study period. Before and after the study, each patient 
underwent physical examination, routine laboratory in- 
vestigation and ECG registration. To avoid adverse ef- 
fects of apomorphine, domperidone 20 mg t.i.d. was 
given. All patients were titrated up to an optimal dose of 
subcutaneous apomorphine HCl (I%, 10 mg/ml), start- 
ing with 1 mg, with subsequent 1 mg increments. The 
maximum dose was 10 mg. Optimal dose was defined as 
the maximum tolerated dose, with the best motor re- 
sponse in combination with minimal adverse effects. In 
the next ten ‘off-periods, with intervals of at least 3 h, 
apomorphine or placebo (0.9% sodiumhydrochloride so- 
lution) was injected with a non-transparent injection pen, 
following a randomization table, of which the key was 
kept by the pharmacist. Each patient was his own control 
in these five n = 1 studies. 
Before and at the time of best motor response, or 0.5 h 
after the injection, the following assessments were made: 
the Columbia rating, a finger/foot-tapping score during 
30 s, a timed walking over 25 m and a timed pinboard 
test, as well as the blood pressure. The Columbia rating 
has 5 items: tremor, rigidity, gait, bradykinesia and sta- 
bility, each scored according to a 5-point scale. The exact 
one-tailed significance probabilities (p) of the mean dif- 
ference-scores of the separate items of the Columbia rat- 
ing scale and the quantitative assessments, were com- 
puted by using the Mann-Whitney test. Also thep-values 
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Placebo Apomorphine 
_ Stability + Bradykinesia + Tremor -0- Gait -* Rigidity 
for every item the combined Mann-Whitney 
statistic yields p<.OOl (see text) 
Fig. 1. Separate Columbia items. Mean difference scores of the separate Columbia items. For every item the combined Mann-Whitney 
statistic yields P < 0.001. 
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for the summed Columbia items were computed, for each 
separate patient. The difference scores of the separate 
quantitative variables were summed. The difference 
scores of walking and pin-board were turned from nega- 
tive into positive, because a shorter time means an im- 
proved result. Each quantitative variable was standard- 
ized (on mean 0 and standard deviation 1) over all trials, 
in order to obtain a sum score to which each of the varia- 
bles contributes approximately equally. Finally, the sum 
score was standardized again and written down the y- 
axis. To get an idea of the most informative combination 
of Columbia items and quantitative assessments, a 
Spearman correlation coefficient was computed for all 
combinations. All assessments were made by one author, 
to eliminate inter-observer variabilities. The same author 
did the run-in of optimal dose finding injections. The 
latency of onset and duration of response were recorded, 
as well as possible adverse effects. 
From each patient 2 time-concentration profiles of 
serum-concentration apomorphine were made in the 
dose-finding series. The first data set was obtained after 
injecting the starting dose of 1 mg and the second after 
giving the optimal dose of apomorphine. After injecting 
1 mg, blood samples were taken according a fixed time- 
schedule t = 0, 3, 6, 9, 12, 15, 30, 45, 60 and 120 min, by 
means of an intravenous catheter. The samples were 
stored at -20°C until analysis by HPLC [9]. 
After injection of the optimal dose, 3 samples, only 
around the T,,,,, from the 1 mg-profile, were taken and 
analyzed. The presence of apomorphine in the blood 
samples was regarded as a control of the randomisation 
table. 
Results 
The mean optimal dose of apomorphine was 2.7 mg 
with a range of l-5 mg. All 5 patients responded very 
well to apomorphine. All patients reported a sudden re- 
lief of their ‘off-symptoms, often accompanied with 
yawning. The latency of onset had a mean value of 7.3 
min (range 1.5-15 min). The mean duration of response 
was 96 min (range 20-120 min). In computing the follow- 
ing data, 3 out of 50 trials (5 patients with 10 trials each) 
were excluded, because the contents of the injection pen, 
according to the list of the pharmacist, did not corre- 
spond with the HPLC-analysis of the serum levels. The 
mean difference scores of the separate Columbia items 
showed a significant improvement of all items, after apo- 
morphine. For every item the combined Mann-Whitney 
statistic yields p < 0.001 (Fig. 1). The most significant 
scores were reached with the items tremor and stability, 
with Z-values ranging from 4.45-4.83. 
The mean difference scores of the sum of Columbia- 
items for each patient are shown in Fig. 2. Only one pa- 
tient did not show a significant improvement of the total 
Columbia score after apomorphine. The other patients 
showed p-values ranging from 0.00-0.03. The combined 
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Placebo Apomorphine 
- Patient 1 (p = .03) + Patient 2 (p = .29) + Patient 3 (p = .Ol) 
+ Patient 4 (p = .OO) + Patient 5 (p = .Ol) 
Combined Mann-Whitney test (see text): 
z = 4.76, p = .OOl 
Fig. 2. Sum of Columbia items. Mean difference scores of the sum of Columbia items. The results of each separate patient are shown. 
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Placebo 
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Apomorphine 
- Patient 1 (p = .06) -+- Patient 2 (p = 50) + Patient 3 (p = .03) 
-8- Patient 4 (p = .OO) ++ Patient 5 (p = .Oi) 
Combined Menn-Whitney test (see text): 
z = 3.79, p = .ooi 
Fig. 3. Sm of quantitative variables. Mean difference scores of the sum of quantitative variables. The results of each separate patient 
are shown. 
Mann-jitney test statistic, in which the results of all 
patients are put together, yielded 2 = 4.76, which re- 
sulted in p = 0.001. This means an overall statistically 
significant positive effect of apomorphine. When ana- 
lyzed separately, the mean difference in the quantitative 
sum scores were not significant better in 2 patients with 
p = 0.06 andp = 0.50 (Fig. 3). After summing the quanti- 
tative variables (pinboard, tapping and walking) of all 
patients, however, there was a significant improvement 
(p = 0.001) after apomorphine vs. placebo, with 
z = 3.79. 
The correlations, computed with the Reagan test, 
between the Columbia items and the quantitative items 
showed some interesting results (Table 1). Tapping 
showed the best correlations with the Columbia items. 
The coefficients ranged from 0.65-0.81, with p < 0.001. 
From these items, especially bradykinesia and rigidity 
correlated very well with tapping. The other items did 
not add much, looking at the correlation coefficient with 
the total Columbia score (0.84). Walking showed the 
highest correlation with gait and stability, as one should 
have expected (correlation coefficients 0.76 and 0.74 re- 
spectivily, p < 0.001). Pinboard testing did not show an 
important correlation with one of the Columbia items. 
Very few adverse effects were reported. Only one pa- 
tient showed nausea, without vomiting. Four patients 
showed dyskinesia, in combination with the maximal re- 
sponse. One patient had short-lasting twinkling in both 
legs. Also one patient had a very short-lasting worsening 
of tremor and another patient complaint about a feel- 
ing of warmth and perspiration, both just before the 
onset of clinical effect. 
Two patients spontaneously reported a lower level of 
motor functioning at the end of clinical effect, as com- 
pared to their basic level before the test. There was no 
influence on blood pressure. Routine laboratory investi- 
gation, ECG and physical examination revealed no ab- 
normalities. The data obtained from the time-concentra- 
tion figures show a mean r,;,, of 10 min (range 7.513 
min) and a mean C,,, of 22 ngfml (range 12-43 nglmt). 
Discussion 
In this study we proved that apomorphine is statisti- 
cally significantly more efficacious, compared to pla- 
cebo, in ‘off-periods in PD. This was shown in the clini- 
cal scoring, as well in the quantitative data. The mean 
optimal dose of apomorphine injection was 2.7 mg, 
which is comparable to data already published by several 
authors [4-41. The same holds true for the latency of 
onset of 7.3 min. Our duration of response (96 min) is 
slightly longer than in most other studies. Only Poewe 
reported a duration of response varying from 1 B-2.5 h. 
after one single injection with apomorphine [lo]. A very 
interesting phenomenon is the worsening at the end of 
motor response and just before onset of clinical effect, 
which might be exptained by an inhibitory feedback ac- 
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TABLE 1 
SPEARMAN CORRELATIONS 
Tapping Walking Pinboard 
1% hydrocortisone creme and/or hyaluron acid (lasonil), 
but give sometimes cosmetic problems. In our experience 
therefore apomorphine deserves an important role in the 
treatment of response fluctuations in Parkinson’s dis- 
ease. 
Rigidity 0.76 0.53 0.52 
Tremor 0.73 0.54 0.46 
Bradykinesia 0.81 0.60 0.55 
Stability 0.68 0.74 0.49 
Gait 0.65 0.76 0.50 
Total Columbia 0.84 0.68 0.53 
P < 0.001 for all correlation coefficients. 
tion of apomorphine on the pre-synaptic dopamine re- 
ceptor [11,12]. 
In this study, tapping showed the highest correlation 
with especially rigidity and bradykinesia and walking 
showed a high correlation with stability and gait. Pin- 
board testing did not add important information. This 
suggests a possibility to reduce our qualitative and quan- 
titative assessments, without losing significant informa- 
tion. From other studies the reliability of the Columbia 
items, with great interobserver agreements, was estab- 
lished [13]. Therefore, based on our results, a combina- 
tion of the Columbia item tremor, which can be scored in 
a short time, combined with tapping and walking scores. 
gives the best information. 
The adverse effects after pretreatment with domperi- 
done were very mild and not disabling. This is a great 
advantage as compared to other dopamine agonists such 
as lisuride and bromocriptine, which produce more psy- 
chiatric and cardiovascular complications [7,14]. One of 
the possible explanations is the anti-psychotic property 
of the piperidine side-chain of apomorphine. The other 
possible adverse effects of apomorphine can succesfully 
be blocked by domperidone. 
Finally, our results show that apomorphine is a signifi- 
cantly effective tool in the management of PD, supported 
by the experiences of many neurologists, but hardly 
proven before. 
Also after long-term treatment (l-3 years) with apo- 
morphine, a significant efficacy can be maintained in al- 
most all patients. Only the optimal dose slightly increases 
and the duration of effect slightly decreases during years 
of treatment. The most important limiting factor for the 
long-term use of subcutaneous apomorphine sometimes 
is the local irritability, leading to e.g. subcutaneous nod- 
ules. These nodules are not harmful, when treated with 
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